EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A gain‐of‐function mutation in microRNA 142 is sufficient to cause the development of T‐cell leukemia in mice

Shingo Kawano iD, Kimi Araki, Jie Bai iD, Imari Furukawa, Keigo Tateishi, Kumiko Yoshinobu, Shingo Usuki, Rachael A Nimmo, Tadashi Kaname iD, Masaharu Yoshihara iD, Satoru Takahashi, Goro Sashida iD und 1 weitere

Cancer Science · 2023

DOI: 10.1111/cas.15794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Shingo Kawano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, MicroRNAs, Myelodysplastic Syndromes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MicroRNAs (miRNAs) play a crucial role in regulating gene expression. MicroRNA expression levels fluctuate, and point mutations and methylation occur in cancer cells; however, to date, there have been no reports of carcinogenic point mutations in miRNAs. MicroRNA 142 (miR‐142) is frequently mutated in patients with follicular lymphoma, diffuse large B‐cell lymphoma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). To understand the role of miR‐142 mutation in blood cancers, the CRISPR‐Cas9 system was utilized to successfully generate miR‐142‐55A>G mutant knock‐in (Ki) mice, simulating the most frequent mutation in patients with miR‐142 mutated AML/MDS. Bone marrow cells from miR‐142 mutant heterozygous Ki mice were transplanted, and we found that the miR‐142 mutant/wild‐type cells were sufficient for the development of CD8 + T‐cell leukemia in mice post‐transplantation. RNA‐sequencing analysis in hematopoietic stem/progenitor cells and CD8 + T‐cells revealed that miR‐142‐Ki/+ cells had increased expression of the mTORC1 activator, a potential target of wild‐type miR‐142‐3p. Notably, the expression of genes involved in apoptosis, differentiation, and the inhibition of the Akt–mTOR pathway was suppressed in miR‐142‐55A>G heterozygous cells, indicating that these genes are repressed by the mutant miR‐142‐3p. Thus, in addition to the loss of function due to the halving of wild‐type miR‐142‐3p alleles, mutated miR‐142‐3p gained the function to suppress the expression of distinct target genes, sufficient to cause leukemogenesis in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMicroRNAsMyelodysplastic SyndromesAnimalsMiceCarcinogenesisCD8-Positive T-LymphocytesGain of Function Mutation

Stichwörter der Autor:innen

acute myeloid leukemiamiR-142microRNAmodel micesingle nucleotide mutation

Substanzen

MicroRNAsMirn142 microRNA, mouse

Autor:innen und Institutionen

  • Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
  • International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Liaison Laboratory Research Promotion Center, IMEG, Kumamoto University, Kumamoto, Japan.
  • Oxford Biomedica (UK) Ltd, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
  • Department of Genome Medicine, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

ORCID-Profile: Shingo Kawano, Jie Bai, Tadashi Kaname, Masaharu Yoshihara, Goro Sashida, Masatake Araki

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Kawano, S., Araki, K., Bai, J., Furukawa, I., Tateishi, K., Yoshinobu, K., Usuki, S., Nimmo, R. A., Kaname, T., Yoshihara, M., Takahashi, S., Sashida, G., & Araki, M. (2023). A gain‐of‐function mutation in microRNA 142 is sufficient to cause the development of T‐cell leukemia in mice. Cancer Science. https://doi.org/10.1111/cas.15794

Vancouver

Kawano S, Araki K, Bai J, Furukawa I, Tateishi K, Yoshinobu K, et al. A gain‐of‐function mutation in microRNA 142 is sufficient to cause the development of T‐cell leukemia in mice. Cancer Science. 2023. doi:10.1111/cas.15794

BibTeX
@article{Kawano2023,
  author = {Kawano, Shingo and Araki, Kimi and Bai, Jie and Furukawa, Imari and Tateishi, Keigo and Yoshinobu, Kumiko and Usuki, Shingo and Nimmo, Rachael A and Kaname, Tadashi and Yoshihara, Masaharu and Takahashi, Satoru and Sashida, Goro and Araki, Masatake},
  title = {A gain‐of‐function mutation in microRNA 142 is sufficient to cause the development of T‐cell leukemia in mice},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15794}
}
Kostenlos starten →